Comparative Effectiveness Research in Heart Failure Therapies. Women, Elderly Patients, and Patients with Kidney Disease.

Heart Failure Clinics

Volumn 9, Issue 1, 2013, Pages 79-92

  Shah, Rashmee U ^a   Chang, Tara I ^b   Fonarow, Gregg C ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic renal insufficiency; Comparative effectiveness; Elderly; Heart failure; Women

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; ZOFENOPRIL;

ACUTE HEART INFARCTION; CARDIOVASCULAR MORTALITY; COMPARATIVE EFFECTIVENESS; DIALYSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CLINICAL PROTOCOLS; COMORBIDITY; COMPARATIVE EFFECTIVENESS RESEARCH; DIALYSIS; DISEASE MANAGEMENT; FEMALE; HEART FAILURE; HUMANS; KIDNEY DISEASES; MALE; METABOLIC DETOXICATION, DRUG; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84869496999     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.09.003     Document Type: Review

References (75)

1. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 1982, 14(4):473-482.
2. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121(7):e46-e215.
3. Heiat A., Gross C.P., Krumholz H.M. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002, 162(15):1682-1688.
4. Masoudi F.A., Havranek E.P., Wolfe P., et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003, 146(2):250-257.
5. Sox H.C., Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009, 151(3):203-205.
6. Wang R., Lagakos S.W., Ware J.H., et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357(21):2189-2194.
7. Schneeweiss S., Rassen J.A., Glynn R.J., et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009, 20(4):512-522.
8. Brookhart M.A., Schneeweiss S., Rothman K.J., et al. Variable selection for propensity score models. Am J Epidemiol 2006, 163(12):1149-1156.
9. D'Agostino R.B. Propensity scores in cardiovascular research. Circulation 2007, 115(17):2340-2343.
10. Shah R.U., Klein L., Lloyd-Jones D.M. Heart failure in women: epidemiology, biology and treatment. Womens Health 2009, 5(5):517-527.
11. Hsich E.M., Pina I.L. Heart failure in women: a need for prospective data. J Am Coll Cardiol 2009, 54(6):491-498.
12. Anonymous Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
13. Ghali J.K., Pina I.L., Gottlieb S.S., et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002, 105(13):1585-1591.
14. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334(21):1349-1355.
15. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344(22):1651-1658.
16. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41(9):1529-1538.
17. Keyhan G., Chen S.F., Pilote L. The effectiveness of beta-blockers in women with congestive heart failure. J Gen Intern Med 2007, 22(7):955-961.
18. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009, 53(2):184-192.
19. Keyhan G., Chen S.F., Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail 2007, 9(6-7):594-601.
20. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362(9386):759-766. [Erratum appears in Lancet 2009 Nov 21-2009 Nov 27;(9703):1744].
21. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717.
22. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348(14):1309-1321.
23. Zannad F., McMurray J.J.V., van Veldhuisen D.J., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364(1):11-21.
24. Anonymous The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997, 336(8):525-533.
25. Rathore S.S., Wang Y., Krumholz H.M., et al. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347(18):1403-1411.
26. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006, 27(2):178-186.
27. Zhou J., Shi H., Zhang J., et al. Rationale and design of the [beta]-blocker in heart failure with normal left ventricular ejection fraction (β-PRESERVE) study. Eur J Heart Fail 2010, 12(2):181-185.
28. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT). 2011. Available at: Accessed January 11, 2011. http://clinicaltrials.gov/ct2/show/NCT00094302.
29. Diastolic Heart Failure Management by Nifedipine (DEMAND). Available at: Accessed January 11, 2011. http://clinicaltrials.gov/ct2/show/NCT01157481.
30. Senni M., Tribouilloy C.M., Rodeheffer R.J., et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999, 159(1):29-34.
31. Curtis L.H., Whellan D.J., Hammill B.G., et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008, 168(4):418-424.
32. Deedwania P.C., Gottlieb S., Ghali J.K., et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004, 25(15):1300-1309.
33. Krum H., Hill J., Fruhwald F., et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail 2006, 8(3):302-307.
34. Flather M.D., Shibata M.C., Coats A.J.S., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26(3):215-225.
35. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355(9215):1575-1581.
36. Masoudi F.A., Rathore S.S., Wang Y., et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004, 110(6):724-731.
37. Masoudi F.A., Krumholz H.M. Polypharmacy and comorbidity in heart failure. BMJ 2003, 327(7414):513-514.
38. Shlipak M.G., Massie B.M. The clinical challenge of cardiorenal syndrome. Circulation 2004, 110(12):1514-1517.
39. Dinsdale C., Wani M., Steward J., et al. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing 2005, 34(4):395-398.
40. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351(6):543-551.
41. Heywood J.T., Fonarow G.C., Costanzo M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007, 13(6):422-430.
42. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109(8):1004-1009.
43. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47(10):1987-1996.
44. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35(3):681-689.
45. Anand I.S., Bishu K., Rector T.S., et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009, 120(16):1577-1584.
46. Shlipak M.G., Smith G.L., Rathore S.S., et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004, 15(8):2195-2203.
47. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283(10):1295-1302.
48. Ghali J.K., Wikstrand J., Van Veldhuisen D.J., et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 2009, 15(4):310-318.
49. Anonymous The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353(9146):9-13.
50. Erdmann E., Lechat P., Verkenne P., et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001, 3(4):469-479.
51. Cohen-Solal A., Kotecha D., van Veldhuisen D.J., et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009, 11(9):872-880.
52. Cice G., Di Benedetto A., D'Isa S., et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010, 56(21):1701-1708.
53. Anonymous Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325(5):293-302.
54. Anonymous Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316(23):1429-1435.
55. Konstam M.A., Neaton J.D., Dickstein K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374(9704):1840-1848.
56. Takahashi A., Takase H., Toriyama T., et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006, 21(9):2507-2512.
57. Suzuki H., Kanno Y., Sugahara S., et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008, 52(3):501-506.
58. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial I A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345(23):1667-1675.
59. McMurray J.J.V., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362(9386):767-771.
60. Bakris G., Vassalotti J., Ritz E., et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int 2010, 78(8):726-736.
61. Anonymous Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327(10):685-691.
62. Ljungman S., Kjekshus J., Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992, 70(4):479-487.
63. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362(9386):772-776.
64. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349(9054):747-752.
65. Wei L., Struthers A.D., Fahey T., et al. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010, 340:c1768.
66. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 119(14):e391-e479.
67. The International Steering Committee on Behalf of the MERIT-HF Study Group. Rationale, Design, and Organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997, 80(9 Suppl 2):54J-58J.
68. Shibata M.C., Flather M.D., Bohm M., et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol 2002, 86(1):77-85.
69. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362(9377):7-13.
70. Poole-Wilson P.A., Cleland J.G., Di Lenarda A., et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail 2002, 4(3):321-329.
71. Anonymous Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342(8875):821-828.
72. Hall A.S., Winter C., Bogle S.M., et al. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J Cardiovasc Pharmacol 1991, 18(Suppl 2):S105-S109.
73. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995, 332(2):80-85.
74. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333(25):1670-1676.
75. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677.